# Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

> **NCT04798677** · NA · COMPLETED · sponsor: **AB Biotek** · enrollment: 72 (actual)

## Conditions studied

- Immunity
- Vaccine Reaction
- Influenza
- Covid19
- Cytokine Storm
- Immunologic Deficiency Syndromes

## Interventions

- **DIETARY_SUPPLEMENT:** ABBC1 Immunoessential
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT04798677
- **Lead sponsor:** AB Biotek
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2021-06-10
- **Final completion:** 2021-09-24
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798677, "Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04798677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*